ALLRMEDIUM SIGNALFINANCIAL10-K

ALLR showed significant operational improvement with losses cut in half, but concerning debt burden increase of over 4,000%.

The dramatic reduction in operating losses from $27.2M to $12.6M suggests improved cost management and operational efficiency. However, the massive spike in interest expense from $12K to $498K indicates substantial new debt obligations that could strain cash flows going forward.

Comparing 2026-03-30 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

ALLR demonstrated strong operational improvement with net losses declining 54% and operating losses cut by nearly half, while simultaneously reducing total liabilities by 22% and maintaining a solid cash position of $14.7M despite a 25% decline. The concerning development is the 4,050% increase in interest expense suggesting significant new debt, though the overall financial picture shows a company successfully reducing its burn rate. Capital expenditures dropped 97% to just $8K, indicating minimal investment in growth but also reflecting disciplined cash management during this operational restructuring phase.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+4050%
$12K$498K

Interest expense surged 4050% — significant debt increase or rising rates materially impacting earnings.

Capital Expenditure
Cash Flow
-97.3%
$298K$8K

Capex reduced 97.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Net Income
P&L
+54.2%
-$24.5M-$11.2M

Net income grew 54.2% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+53.7%
-$27.2M-$12.6M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Cash & Equivalents
Balance Sheet
-24.8%
$19.5M$14.7M

Cash decreased 24.8% — monitor burn rate and upcoming capital needs.

Total Liabilities
Balance Sheet
-22.2%
$10.8M$8.4M

Liabilities reduced 22.2% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-22.2%
$10.8M$8.4M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
-19.8%
$22.3M$17.9M

Current assets declined 19.8% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-19.4%
$22.6M$18.3M

Total assets contracted 19.4% — asset sales, write-downs, or balance sheet optimization underway.

Stockholders Equity
Balance Sheet
-16.8%
$11.8M$9.8M

Equity decreased 16.8% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-31
ADDED
false --12-31 FY 2025 true true true It is expected that IT governance and cybersecurity will be included in our quarterly management review meetings under the supervision of our senior leadership, including our Chief Executive Officer and Chief Financial Officer.
Senior management regularly meets with and provides periodic briefings to our board of directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.
It is expected that IT governance and cybersecurity will be included in our quarterly management review meetings under the supervision of our senior leadership, including our Chief Executive Officer and Chief Financial Officer.
Senior management regularly meets with and provides periodic briefings to our board of directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.
It is expected that IT governance and cybersecurity will be included in our quarterly management review meetings under the supervision of our senior leadership, including our Chief Executive Officer and Chief Financial Officer.
+7 more — sign up free →
REMOVED
As of March 31, 2025, there were 17,014,737 shares of the registrant s common stock outstanding.
References in this Annual Report to our therapeutic candidate, our therapeutic candidate, stenoparib, or stenoparib refer to our sole current therapeutic candidate, stenoparib.
In the second half of 2023, we seated two new independent directors to our board of directors, Laura E.
Jensen is a co-founder of Allarity and has extensive experience not only with the core DRP platform technology but also with capital fund raising.
In the second half of 2024, we added a new Chief Financial Officer, Mr.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →